As he leaves after 23 years at the firm, outgoing CEO Eric-Paul Pâques talks about Grünenthal's growth and strategic priorities under his leadership while its new head, Gabriel Baertschi, brings his own brand of energy.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
